RFK Jr SSRI Plan: What HHS Announced, What It Denied, and What Happens Next on Medicare Deprescribing
By The USA HeadlineX News Desk
Updated: 2 November 2026
The RFK Jr SSRI plan what happens next Medicare deprescribing question has a dated answer, and the date matters. The plan at the centre of it was announced on 4 May 2026, not in November 2026. Confirmed: on 4 May 2026, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., announced a “MAHA Action Plan” to curb what it called psychiatric overprescribing, including guidance on how clinicians can be paid under Medicare for deprescribing-related care. Reported, and denied by HHS: that HHS officials had explored banning certain SSRI antidepressants before the announcement — a report based on two unnamed sources, which HHS spokesman Andrew Nixon denied to Reuters. Not confirmed as of 2 November 2026: any ban, any restriction on access to SSRIs, or any published formal HHS clinical guidance on deprescribing arising from the plan. This article separates what HHS published from what was reported anonymously, and from what experts said in response.
Reporting note: Do not change medication without your clinician. This article reports what a federal plan said and what experts said about it. It is not medical advice, and it does not advise any individual to start, stop, or change any medication. Anyone with questions about their own treatment should speak to their own clinician. HHS’s own announcement directed people in crisis to call or text 988 or visit 988lifeline.org.
What SSRI and deprescribing mean
SSRI stands for selective serotonin reuptake inhibitor, a class of antidepressants including fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil). Reuters noted in May 2026 that SSRIs had been available in the United States for decades, were widely available in generic form, and are considered by the American Psychiatric Association a first-option, evidence-based treatment for depression, used also for several anxiety disorders.
“Deprescribing” is the term used in the HHS plan for reducing or stopping a medicine, with monitoring, when clinically indicated — when a clinician and patient judge together that it is no longer providing benefit, or that its risks outweigh its benefits for that patient. It is distinct, in the plan’s own framing, from stopping abruptly or without clinical review. That distinction matters, because the dispute around the plan is largely about whether federal messaging and payment signals encourage careful, individual review or create pressure beyond it.
About one in six U.S. adults reported currently taking antidepressant medications, according to a 2026 study in BMJ Mental Health cited by Reuters in May 2026, with SSRI drugs the most common type. That figure describes use, not overuse: whether a prescription is appropriate depends on the individual patient, which no national total can show.
What HHS announced on 4 May 2026
HHS announced the plan at a summit held by the Make America Healthy Again (MAHA) Institute on mental health and overmedicalization, with Secretary Kennedy as the closing speaker. The department’s press release, dated 4 May 2026, is the primary record, and this section follows it closely.
Kennedy framed the plan as a response to a mental-health crisis and to overuse of psychiatric medicines, with particular emphasis on children. The release quoted him: “Today, we take clear and decisive action to confront our nation’s mental health crisis by addressing the overuse of psychiatric medications — especially among children. We will support patient autonomy, require informed consent and shared decision-making, and shift the standard of care toward prevention, transparency, and a more holistic approach to mental health.”
Three operational elements were spelled out. First, a “Dear Colleague” letter to providers, published the same day, encouraged informed consent and shared decision-making, regular review of risks and benefits with patients, and non-medication approaches — family support, psychotherapy, nutrition, and physical activity — when clinically appropriate. It also gave information on billing codes that can support evidence-based non-medication treatments.
Second, the Centers for Medicare & Medicaid Services (CMS) released guidance on deprescribing and related care. According to HHS, it clarified how clinicians can be paid for this care under Medicare and directed them to recognised resources, including professional guidelines, peer-reviewed protocols, and FDA taper-schedule instructions. HHS described a clarification of payment, not new rates, newly created codes, or any change to covered medicines. Secondary reporting described the element as using existing rates and codes and as Medicare-only — flagged here as secondary reporting, not HHS’s wording.
Third, HHS listed upcoming activities: a SAMHSA prescribing-trends report and fact sheet in May 2026; SAMHSA webinars in June and July; a joint SAMHSA/HRSA webinar for Federally Qualified Health Center providers; and a Technical Expert Panel in July to inform formal HHS clinical guidance on use, tapering, and discontinuation. CMS was also to expand access to non-medication care for children and adolescents.
The ban report — and the HHS denial, side by side
On 8 May 2026, Reuters reported that health department officials “last week explored whether they could ban certain drugs in a widely prescribed class of antidepressants” as Kennedy prepared to roll out the plan, “according to two people familiar with the discussions.” Their interest centred on specific SSRIs such as Zoloft, Prozac, and Lexapro, but the sources “did not say which drugs were being examined for restrictions or how far the inquiries about them had advanced.” Reuters did not name officials, publish documents, or claim a ban had been decided. It described an exploration, not a ban itself.
HHS denied the report in the same article, in a statement from spokesman Andrew Nixon: “HHS has not had any discussions about banning SSRIs, and any claims suggesting otherwise are false.” The two accounts cannot both be complete, and the published record alone cannot resolve the conflict. What can be said is that no ban followed: no SSRI was withdrawn or restricted under the plan, and no ban document has been published.
The legal context, as Reuters reported from drug-approval experts, is that the FDA, not HHS, has authority over antidepressant use, and new restrictions would require strong scientific evidence of a risk outweighing benefits, with review taking months or years. The FDA cannot unilaterally ban already-approved, long-available medicines without new evidence of a safety problem or a finding of false statements in the original application.
RFK Jr SSRI plan what happens next Medicare deprescribing: what experts said
The American Psychiatric Association, in a statement after the announcement reported by Reuters, said it supported better research to help physicians prescribe treatments and decide when a patient can come off them, but “strongly objected to framing the nation’s mental health crisis as primarily a problem of ‘overmedicalization’ or ‘overprescribing’.”
Its president, Dr. Theresa Miskimen Rivera, told NPR in May 2026 that blaming the crisis on overmedicalization and overprescription was an “oversimplification” that ignored that too many patients could not access timely, comprehensive care. She supported better training and investment in research and evidence-based treatment, and listed workforce shortages, limited beds, inadequate visit time, and barriers to psychotherapy among factors the framing did not take into account.
Other cautions focused on deprescribing done badly or under pressure. The American Foundation for Suicide Prevention, as reported by Psychiatric Times, cautioned that non-collaborative or abrupt deprescribing might precipitate relapse and elevate suicide risk, stressing individualised assessment and close follow-up. Dr. Mark Olfson of Columbia University told Reuters that although SSRIs carry real risks, “abrupt policy efforts that stigmatize or limit access could produce serious public-health consequences for patients who rely on them.”
Kennedy’s earlier claims were also part of the coverage, and Reuters reported them with an explicit evidence qualification: Kennedy had, “without evidence,” linked SSRIs to violence, including mass shootings, and said they pose a risk to foetuses in pregnancy, and had previously said SSRI withdrawal symptoms were worse than those from heroin. This article reports those as Kennedy’s claims, with Reuters’ qualification. It makes no claim about any individual’s health or diagnosis.
Support for elements of the plan also came from outside the psychiatric establishment. The Citizens Commission on Human Rights — established in 1969 by the Church of Scientology and Professor Thomas Szasz — applauded the focus on informed consent and safe tapering. It is not a medical body, and its support is not clinical evidence. Separately, professionals had themselves pushed for more discontinuation research, including new guidelines published by the American Society of Clinical Psychopharmacology in February 2026.
What happens next — and what could not be verified
As of 2 November 2026, the verifiable “what happens next” is narrower than the May timetable suggested. What could be verified is that the SAMHSA report, webinars, Technical Expert Panel, and CMS work were announced and scheduled. What could not be verified is whether the SAMHSA report was published, what it found, whether the panel met, or whether formal HHS clinical guidance has since been published. Those outcomes are not claimed here; if published, they belong in an update with their own dates and sources.
No new federal action on SSRIs in October or November 2026 was verified either: no ban, restriction, coverage change, or new guidance dated in those months appears in the HHS or Reuters/AP/BBC record checked here. The finding is a May plan, a May denial, and scheduled follow-ups whose published outcomes remain unverified — not a new November announcement.
Separately, on personnel: The Free Press reported on 2 November 2026 that Laura Delano was starting that day as a senior policy adviser at HHS, to help set guidance for tapering off antidepressants. No HHS statement confirming the appointment was found in the checks for this re-check.
What would change the picture follows from the plan’s structure: any formal HHS clinical guidance, any CMS action changing payment or coverage beyond the May clarification, any FDA action on any SSRI, and any published SAMHSA report — each with its own date and source.
For patients and clinicians, the practical position as of 2 November 2026 is the position the plan stated: no instruction from HHS to stop any medicine, an emphasis on shared decision-making and regular review, and payment clarification for deprescribing-related care under Medicare. The reporting note at the top stands for any individual decision: do not change medication without your clinician.
Frequently asked questions
Did HHS ban SSRIs?
No ban was announced or has taken effect. Reuters reported in May 2026, citing two unnamed sources, that HHS officials had explored whether certain SSRIs could be banned. HHS spokesman Andrew Nixon denied that, saying HHS “has not had any discussions about banning SSRIs, and any claims suggesting otherwise are false.” No ban document has been published.
What did the HHS plan actually announce on 4 May 2026?
A “MAHA Action Plan” to promote appropriate prescribing and deprescribing when clinically indicated: a Dear Colleague letter on informed consent, CMS guidance clarifying Medicare payment for deprescribing-related care, SAMHSA education and a prescribing-trends report, a July Technical Expert Panel, and work to expand non-medication care.
Does the plan change what Medicare covers?
On HHS’s own wording, the May CMS guidance clarified how clinicians can be paid for deprescribing-related care under Medicare and pointed to existing clinical resources. It did not announce that any medicine would stop being covered. Secondary reporting described the guidance as using existing rates and codes and as Medicare-only. Any future change would need its own dated CMS document.
What happens next, as of 2 November 2026?
No new ban, restriction, or formal guidance was verified, and the outcomes of the SAMHSA report and July panel could not be verified. Watch for a published SAMHSA report, formal HHS guidance, new CMS guidance, and any FDA action — each with its own date and source.
SOURCES
- U.S. Department of Health and Human Services, “HHS Launches MAHA Action Plan to Curb Psychiatric Overprescribing,” 4 May 2026: https://www.hhs.gov/press-room/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing.html
- Reuters, “Kennedy’s health officials explored US ban of some widely used antidepressants,” 8 May 2026 (Abutaleb and Erickson): https://www.reuters.com/business/healthcare-pharmaceuticals/kennedys-health-officials-explored-us-ban-some-widely-used-antidepressants-2026-05-08/
- NPR / Central Florida Public Media, “Psychiatrists say RFK Jr.’s take on SSRIs is an ‘oversimplification’ of the problem,” 7 May 2026 (Dr. Theresa Miskimen Rivera, American Psychiatric Association): https://www.cfpublic.org/2026-05-07/psychiatrists-say-rfk-jr-s-take-on-ssris-is-an-oversimplification-of-the-problem
- HealthDay / Drugs.com, “RFK Jr. Launches Plan To Curb Antidepressant ‘Overprescription’,” 8 May 2026 (HHS release and Dr. Miskimen Rivera): https://www.drugs.com/news/rfk-jr-launches-plan-curb-antidepressant-overprescription-129955.html
- Psychiatric Times, “HHS Launches Action Plan to Promote ‘Appropriate Psychiatric Prescribing’,” 5 May 2026 (APA and American Foundation for Suicide Prevention responses): https://www.psychiatrictimes.com/view/hhs-launches-action-plan-to-promote-appropriate-psychiatric-prescribing
- Alston & Bird, Health Care Week in Review (JD Supra), “HHS Launches MAHA Action Plan on Psychiatric Prescribing,” May 2026 (CMS guidance and SAMHSA/Technical Expert Panel timetable): https://www.jdsupra.com/legalnews/health-care-week-in-review-hhs-launches-7317869/
- The Free Press, “She Spent 14 Years on Psychiatric Drugs. Now She’s Joining HHS to Fix the System,” 2 November 2026: https://www.thefp.com/p/laura-delano-maha-hhs-rfk-psychiatry
